TransCode Therapeutics Statistics

Total Valuation

RNAZ has a market cap or net worth of $1.84 million. The enterprise value is $118,287.

Market Cap	1.84M
Enterprise Value	118,287

Important Dates

The last earnings date was Thursday, November 14, 2024, after market close.

Earnings Date	Nov 14, 2024
Ex-Dividend Date	n/a

Share Statistics

RNAZ has 523,201 shares outstanding.

Current Share Class	523,201
Shares Outstanding	523,201
Shares Change (YoY)	n/a
Shares Change (QoQ)	+108.27%
Owned by Insiders (%)	0.04%
Owned by Institutions (%)	1.88%
Float	523,016

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	6.02
PB Ratio	1.11
P/TBV Ratio	1.11
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.58, with a Debt / Equity ratio of 0.09.

Current Ratio	1.58
Quick Ratio	0.82
Debt / Equity	0.09
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-346.50

Financial Efficiency

Return on equity (ROE) is -490.03% and return on invested capital (ROIC) is -268.05%.

Return on Equity (ROE)	-490.03%
Return on Assets (ROA)	-129.43%
Return on Capital (ROIC)	-268.05%
Revenue Per Employee	n/a
Profits Per Employee	-$1.49M
Employee Count	10
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -98.59% in the last 52 weeks. The beta is 0.55, so RNAZ's price volatility has been lower than the market average.

Beta (5Y)	0.55
52-Week Price Change	-98.59%
50-Day Moving Average	12.72
200-Day Moving Average	20.22
Relative Strength Index (RSI)	23.01
Average Volume (20 Days)	88,095

Short Selling Information

The latest short interest is 52,411, so 10.02% of the outstanding shares have been sold short.

Short Interest	52,411
Short Previous Month	605,720
Short % of Shares Out	10.02%
Short % of Float	10.02%
Short Ratio (days to cover)	0.50

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-14.67M
Pretax Income	-17.06M
Net Income	-14.93M
EBITDA	-14.55M
EBIT	-14.67M
Earnings Per Share (EPS)	-$71.81

Full Income Statement

Balance Sheet

The company has $1.88 million in cash and $152,481 in debt, giving a net cash position of $1.72 million or $3.29 per share.

Cash & Cash Equivalents	1.88M
Total Debt	152,481
Net Cash	1.72M
Net Cash Per Share	$3.29
Equity (Book Value)	1.65M
Book Value Per Share	3.16
Working Capital	1.33M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$15.85 million and capital expenditures -$21,261, giving a free cash flow of -$15.87 million.

Operating Cash Flow	-15.85M
Capital Expenditures	-21,261
Free Cash Flow	-15.87M
FCF Per Share	-$30.34

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

RNAZ does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-810.49%
FCF Yield	-861.96%

Analyst Forecast

The average price target for RNAZ is $20.00, which is 468.18% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$20.00
Price Target Difference	468.18%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on December 4, 2024. It was a reverse split with a ratio of 0.030303:1.

Last Split Date	Dec 4, 2024
Split Type	Reverse
Split Ratio	0.030303:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a